Nuevo coronavirus SARS-COV-2 y enfermedad COVID-19 La pandemia que cambió al mundo.
Recomendaciones de la Sociedad Argentina de Hematología

Palabras clave


Cómo citar

Herrera, F. (2020). Nuevo coronavirus SARS-COV-2 y enfermedad COVID-19 La pandemia que cambió al mundo. Revista Hematología, 24(Extraordin), 4–12. Recuperado a partir de


A fines de diciembre de 2019 varios centros de salud de Wuhan, provincia de Hubei, China, informaron la atención a grupos de pacientes con neumonía de causa desconocida que estaban vinculados epidemiológicamente a un mercado mayorista de mariscos y animales silvestres. El patógeno fue identificado como un nuevo coronavirus, finalmente denominado coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2), que tiene una similitud filogenética con el SARS-CoV, y que causa la enfermedad por coronavirus 19 (COVID-19)(1). 

La infección comenzó a esparcirse rápidamente, primero por China y luego por el resto del planeta, haciendo que la OMS declare formalmente la pandemia el 11 de Marzo de 2020, cuando se habían diagnosticado más de 118.000 casos en 114 países(2).

Desde ese momento el mundo entero ya no fue el mismo.



1. Zhu N, Zhang D, Wang W y col. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733.
2. WHO Director-General's opening remarks at the media briefing on COVID-19- 11 March 2020.
3. Su S, Wong G, Shi W y col. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502.
4. Zhong NS, Zheng BJ, Li YM y col. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003;362:1353-8.
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J
Med 2012;367:1814-20.
6. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.
7. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J Clin Med. 2020 Mar 31;9(4). doi:10.3390/jcm9040967.
8. Johns Hopkins University Coronavirus Resource Center
9. Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020 Mar 6. doi:10.1002/jmv.25749.
10. Modes of transmission of virus causing COVID-19. WHO reference number: WHO/2019-nCoV/Sci_Brief/Transmission_modes/2020.1
11. van Doremalen N, Bushmaker T, Morris DH y col. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17.
doi: 10.1056/NEJMc2004973.
12. Li C, Ji F, Wang L y col. Wang L, Hao J, Dai M, Liu Y, Pan X, Fu J, Li L, Yang G, Yang J, Yan X, Gu B. Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7). doi: 10.3201/eid2607.200718.
13. Wei W; Li Z; Chiew C; y col. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23-March 16, 2020. MMWR 2020; April 1, vol 69: 1-5
14. Kimball A, Hatfield KM, Arons M y col. CDC COVID-19 Investigation Team. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13): 377-381.
15. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13;27(2).
pii: taaa021. doi: 10.1093/jtm/taaa021.
16. Kolifarhood G, Aghaali M, Mozafar Saadati H y col. Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. Arch Acad Emerg Med. 2020 Apr 1;8(1):e41.
17. Wang C, Zhou YH, Yang HX, Poon LC. Intrauterine vertical transmission of SARS-CoV-2: what we know so far. Ultrasound Obstet Gynecol. 2020 Apr 7. doi:10.1002/uog.22045.
18. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev. 2020 Feb 21. pii: S0887-7963(20)30014-6. doi:10.1016/j.tmrv.2020.02.003.
20. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020 Apr 2. doi: 10.1007/s11684-020-0767-8.
21. Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. pii: S1201-9712(20)30204-6. doi: 10.1016/j.ijid.2020.03.071.
22. Chu H, Chan JF, Wang Y y col. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 2020 Apr 9. pii: ciaa410. doi: 10.1093/cid/ciaa410.
23. To KK, Tsang OT, Leung WS y col. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30196-1.doi: 10.1016/S1473-3099(20)30196-1.
24. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020 Mar 28:105951. doi: 10.1016/j.ijantimicag.2020.105951.
25. Sarzi-Puttini P, Giorgi V, Sirotti S y col. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020; 38(2):337-342.
26. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020 Mar 14. doi: 10.1002/jmv.25766.
27. Guan WJ, Ni ZY, Hu Y y col. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28. doi: 10.1056/NEJMoa2002032.
28. Wang D, Hu B, Hu C y col. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585.
29. Chen N, Zhou M, Dong X y col. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223):507-513.
30. Huang C, Wang Y, Li X y col. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223):497-506.
31. Han H, Yang L, Liu R y col. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Mar 16. pii: /j/cclm.ahead-of-print/cclm-2020-0188/cclm-2020-0188.xml. doi: 10.1515/cclm-2020-0188.
32. Shi H, Han X, Jiang N y col. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20 (4): 425-434.
33. Zhou F, Yu T, Du R y col. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229):1054-1062.
34. Shi S, Qin M, Shen B y col. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25. doi: 10.1001/jamacardio.2020.0950.
35. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microbes Infect. 2020; 9 (1):747-756.
36. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Mar 16. pii: /j/cclm.ahead-of-print/cclm-2020-0285/cclm-2020-0285.xml. doi: 10.1515/cclm-2020-0285.
37. Ai T, Yang Z, Hou H y col. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Feb 26:200642. doi: 10.1148/radiol.2020200642.
38. Chen W, Lan Y, Yuan X,y col. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020; 9 (1):469-473.
39. Guo L, Ren L, Yang S y col. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Mar 21. pii:ciaa310. doi: 10.1093/cid/ciaa310.
40. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020 Mar 23. pii: AAC.00483-20. doi: 10.1128/AAC.00483-20.
41. Grein J, Ohmagari N, Shin D y col. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10. doi: 10.1056/NEJMoa2007016.
42. Cao B, Wang Y, Wen D y col. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282.
43. Gautret P, Lagier JC, Parola P y col. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi:10.1016/j.ijantimicag.2020.105949.
44. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 ; 395 ( 10223):473-475.
45. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020 Apr 6. doi: 10.1002/jmv.25801.
46. Shen C, Wang Z, Zhao F y col. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.4783.
47. Duan K, Liu B, Li C y col. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 6. pii: 202004168. doi:10.1073/pnas.2004168117.
48. Nussbaumer-Streit B, Mayr V, Dobrescu AI y col. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.
Cochrane Database Syst Rev. 2020 Apr 8;4:CD013574. doi: 10.1002/14651858.CD013574.
49. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. WHO/2019-nCoV/IPC/v2020.2.
50. CDC: Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission.
51. Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis. 2020 Mar 30;90(1). doi: 10.4081/monaldi.2020.1289.
52. Liang W, Guan W, Chen R y col. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335-337.
53. Ogimi C, Waghmare AA, Kuypers JM y col. Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. Clin Infect Dis. 2017; 64 (11):1532-1539.
54. Food and Drug Administration. Important Information for Human Cell, Tissue, or Cellular or Tissuebased Product (HCT/P) Establishments Regarding the 2019 Novel Coronavirus Outbreak February 14, 2020. Available from: biologics/important-information-human-cell-tissue-or-cellular-or-tissue-based- product-hctp-establishments.
55. Styczynski J, Mikulska M, Ljungman P. EBMT recommendation on: CORONAVIRUS DISEASE COVID- 19: EBMT; 2020 [updated 03/01/2020]. Available from:
56. Dholaria B, Savani BN. How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat? Br J Haematol. 2020 Mar 16. doi: 10.1111/bjh.16597.
57. Recomendaciones por el nuevo coronavirus SARSCOV2 en pacientes con trasplante de células progenitoras hematopoyéticas y oncohematológicos. En:

Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo:


Los datos de descargas todavía no están disponibles.